Fate Therapeutics Inc (FATE)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$1.13

Buy

$1.15

arrow-up$0.04 (+3.60%)

Prices updated at 13 Dec 2025, 00:34 EST

Prices minimum 15 mins delay

Prices in USD

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. William H. Rastetter,PhD

CEO

Dr. Bahram Valamehr, M.B.A.,PhD

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

181

Head office

12278 Scripps Summit Drive

San Diego

United States

92131

+1 858 875-1800

info@fatetherapeutics.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Matthew C. Abernethy Independent Director	-
Dr. Bahram Valamehr, M.B.A.,PhD Director, President and Chief Executive Officer	0.53m
Mr. Kamal Adawi, M.B.A.,M.S. Chief Financial Officer and Principal Accounting Officer	-
Dr. William H. Rastetter,PhD Chairman of the Board	0.08m
Dr. Robert S. Epstein, M.D.,M.S. Independent Director	0.06m
Ms. Cindy R. Tahl, J.D. Chief Legal and Compliance Officer and Corporate Secretary	0.50m
Dr. Shefali Agarwal, M.D.,M.P.H. Independent Director	0.06m
Mr. Michael Lee Independent Director	0.05m
Dr. Karin Jooss, PhD Independent Director	0.06m
Dr. Yuan Xu, PhD Independent Director	0.05m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Redmile Group, LLC	12,872,946
BlackRock Inc	10,680,727
BlackRock, Inc.	10,473,250
Vanguard Group Inc	8,766,764
Wilshire Advisors	8,486,822

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Jul 2024	-
29 Jul 2024	-
29 Jul 2024	-
07 Jun 2024	-
07 Jun 2024	-
07 Jun 2024	-
07 Jun 2024	-
07 Jun 2024	-
07 Jun 2024	-
07 Jun 2024	-
04 Mar 2024	-
01 Feb 2024	-
01 Feb 2024	-
01 Feb 2024	-
01 Feb 2024	-
29 Jan 2024	-
09 Jan 2024	-
09 Jan 2024	-
09 Jan 2024	-
09 Jan 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.